✉news HealthMedicine first seen 7 h ago, last 26 min ago, peak #6
Insilico Medicine picks AI-designed obesity drug candidate ISM1354
Original: Insilico Medicine nominates AI-designed ISM1354 GIPR antagonist for obesity
Drug discovery company Insilico Medicine has nominated ISM1354, an AI-designed GIPR antagonist, as a preclinical drug candidate for the treatment of obesity. The compound was developed using the firm's artificial intelligence drug discovery platform, adding to a growing pipeline of AI-generated molecules advancing toward clinical development for metabolic disease.
Why now: AI-designed drugs for obesity are drawing attention amid intense interest in new weight-loss therapies.
Rank over time, top of the chart is #1. 6 snapshots from 7 h ago to 26 min ago.
Evidence
- Insilico Medicine nominates AI-designed ISM1354 GIPR antagonist for obesity · Drug Target Review
API: https://socialmediatrends-api.osmike.com/v1/trends/751507